Von Hippel-Lindau (VHL) Gene Mutation Analysis
Von Hippel-Lindau (VHL) is a tumor suppressor gene located on chromosome 3. Therefore, the mutation of the VHL gene increases the risk of developing cancer. Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign neoplasms, most frequently retinal, cerebellar, and spinal hemangioblastoma, renal cell carcinoma (RCC), pheochromocytoma, and pancreatic tumors. Early identification of VHL-associated neoplasia can significantly improve the clinical outcome, therefore, genetic testing of the presymptomatic high-risk individual should be used.
VHL mutation is associated with heterozygous germline loss-of-function sequence variants, small deletions or insertions (approx. 80% of cases), or large germline deletions (approx. 20% of cases) of the VHL gene. Approximately 20% of cases are due to de novo pathogenic variants.
Clinically, VHL disease can be subclassified on the basis of absence (Type 1) or presence (Type 2) of pheochromocytoma. VHL Type 1 is associated with pathogenic truncating or missense variants that are predicted to grossly disrupt the folding of VHL protein and are at high risk for hemangioblastoma, renal cell carcinoma, pancreatic cysts, and neuroendocrine tumors. VHL Type 2 is associated with pathogenic missense variants. Patients with VHL Type 2A have an increased risk for pheochromocytoma, retinal angiomas, and CNS hemangioblastoma, but low risk for renal cell carcinoma. VHL Type 2B patients are at high risk for pheochromocytoma, CNS hemangioblastoma, pancreatic cysts, neuroendocrine tumor and renal cell carcinoma, while VHL Type 2C have a higher risk to develop pheochromocytoma only.
In addition, pathogenic sequence variants distinct from those associated with VHL syndrome can cause hereditary erythrocytosis or polycythemia. Erythrocytosis due to VHL is caused by germline homozygous or compound heterozygous pathogenic sequence variants, and is inherited in an autosomal recessive manner. These patients are at higher risk for the development of cerebrovascular and embolic complication, but do not typically develop tumors associated with VHL syndrome.
- As an aid in diagnosis of suspected Von Hippel-Lindau disease
- Useful for confirming diagnosis of Von Hippel-Lindau-associated polycythemia
- Useful in the differential diagnosis of familial pheochromocytoma
- Diagnosis of suspected Von Hippel-Lindau-related hereditary erythrocytosis
- Useful in determination of risk of Von Hippel-Lindau associated tumor
Negative for mutations analyzed (Mutation not detected)
Whole blood (EDTA, Lavender tube).
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Handb Clin Neurol. 2015;132:139-56. [PMID: 26564077]
- Horm Res Paediatr. 2015;84(3):145-52. [PMID: 26279462]
- Hum Mutat. 2007;28(2):143-9. [PMID: 17024664]
- J Clin Endocrinol Metab. 2003;88(3):969-74. [PMID: 12629069]
- Lancet. 2003;361(9374):2059-67. [PMID: 12814730]
- Expert Rev Mol Med. 2001;2001:1-27. [PMID: 14987375]
- Medicine (Baltimore). 1997;76(6):381-91. [PMID: 9413424]